Cetuximab-associated elongation of the eyelashes: Case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors

American Journal of Clinical Dermatology

Volumn 12, Issue 1, 2011, Pages 63-67

  Cohen, Philip R ^a,b,c   Escudier, Susan M ^d   Kurzrock, Razelle ^e  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c University of Texas Health Science Center at Houston   (United States)

^d TEXAS ONCOLOGY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cetuximab, adverse reactions; Epidermal growth factor inhibitors, adverse reactions; Eye; Hypertrichosis, drug induced; Monoclonal antibodies, adverse reactions; Trichomegaly, drug induced

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; EYELASH; EYELASH TRICHOMEGALY; FEMALE; HAIR DISEASE; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; PRIORITY JOURNAL; RECTUM CARCINOMA; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; EYELASHES; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS;

EID: 78649684719     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11531920-000000000-00000     Document Type: Article

References (47)

1. Melichar B, Nemcova I. Eye complications of cetuximab therapy. Eur J Cancer Care 2007; 16: 439-43
2. Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetux-imab (erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008; 27: 612-4
3. Vano-Galvan S, Moreno-Martin P, Jaen P. Progressive trichomegaly [photo quiz]. Neth J Med 2009; 67: 35-6
4. Bouche O, Brixi-Benmansour H, Bertin A, et al. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16: 1711-2
5. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009; 161: 515-21
6. Marquez G, Herrera-Acosta E, Vidal I, et al. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (tarceva) [letter]. Int J Dermatol 2009; 48: 97-8
7. Lacouture ME, Boerner SA, LoRusso PM. Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer 2006; 8 Suppl. 1: S36-42
8. Mitchell EP, Perez-Soler R, Van Cutsem E, et al. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology 2007; 21 (11 Suppl. 5): 4-9
9. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nursing 2006; 22: 152-62
10. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-12
11. Robert C, Soria J-C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500
12. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents tar-geting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Ther Lett 2007; 12 (6): 1-5
13. Bovenschen HJ, HansAlkemade JAC. Erlotinib-induced dermatologic side-effects [letter]. Int J Dermatol 2009; 48: 326-8
14. Deslandres M, Sibaud V, Chevreau C, et al. Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors [in French]. Annales Dermatologie 2008; 1: 16-24
15. Agero ALC, Dusza SW, Benvenuto-AndradeC,etal. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70
16. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33
17. Graves JE, Jones BF, Lind AC, et al. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 2006; 55: 349-53
18. Cowen EW. Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy. J Am Acad Dermatol 2007; 56: 514-7
19. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic ex-ternal ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 2007; 26: 858-60
20. Monti M, Motta S. Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers 2007; 22 Suppl. 4: S53-61
21. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the epidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76
22. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23: 165-74
23. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regu-latory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome [letter]. Br J Dermatol 2006; 155: 852-54
24. Roe E, Muret MPG, Marcuello E, et al. Description and management of cu-taneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55: 429-37
25. Drelich DA, Rose L, Ramirez M, et al. Dermatological toxicities of pan-itumumab in the treatment of patients with metastatic colorectal cancer (mCRC) from three clinical studies [abstract no. 14551]. JClin Oncol 2007 Jun 20; 25 (18 Suppl.): 629s
26. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alter-nations inpatients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601
27. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007; 30 (4 Suppl. 1): S10-6
28. Garibaldi DC, Adler RA. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007; 23: 62-3
29. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 2007; 23: 63-5
30. Lacouture ME, Basti S, Patel J, et al. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006; 4: 236-8
31. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with EGFR inhibitor erlotinib. Dermatol Online J 2009; 15 (3): 4
32. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol 2006; 1: 1040-1
33. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erloti-nib. J Clin Oncol 2008; 26: 3460-2
34. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Re-constr Surg 2007; 23: 65-6
35. Papadopoulos R, Chasapi V, Bachariou A. Trichomegaly induced by erlotinib. Orbit 2008; 35: 329-30
36. Vaccaro M, Pollicino A, Barbuzza O, et al. Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 2008; 34: 402-3
37. Bagazgoitia L,Aboin S, BeaA,et al. Trichomegaly duetocetuximab. Med Clin (Barc) 2009; 133: 323
38. Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncologica 2003; 42: 345-6
39. Hilton L.Skin 'walking wounded' ofcancer tx: anticipating, treating cutaneous side effects keys to quality of life, compliance. Dermatology Times 2007 Mar 1; 28 [online]. Available from URL: http://license.icopyright.net/user/ view FreeUse.act?fuid=NDIzMzM2Mw%3D%3D [Accessed 2009 Jul 23]
40. Kerob D, Dupuy A, Reygagne P, et al. Facial hypertrichosis induced by cetux-imab, an anti-EGFR monoclonal antibody. Arch Dermatol 2006; 142: 1656-7
41. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317-26
42. Pascual JC, BanulsJ, Belinchon I, etal. Trichomegaly following treatment with gefitinib (ZD1839) [letter]. Br J Dermatol 2004; 151: 1111-2
43. Montagut C, Grau JJ, Grimalt R, et al. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 2005; 23: 5273-5
44. Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7
45. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erloti-nib (Tarceva) and gefitinib (Iressa). Oncologist 2005; 10: 579-89
46. Murillas R, Larcher F, Conti CJ, et al. Expresssion of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14: 5216-23
47. Nanney LB, Stoscheck CM, King Jr LE, et al. Immunolocalization of epi-dermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94: 742-8